Explant rates of electrical neuromodulation devices in 1177 patients in a single center over an 11-year period

Reg Anesth Pain Med. 2020 Nov;45(11):883-890. doi: 10.1136/rapm-2020-101681. Epub 2020 Aug 26.

Abstract

Introduction: The publication of explant rates has established risk factors and a definitive objective outcome of failure for spinal cord stimulation (SCS) treating neuropathic pain. We present a UK study analyzing explants of electrical neuromodulation devices for different conditions over 11 years in a single center specializing in neuromodulation.

Methods: A retrospective analysis was performed using a departmental database between 2008 and 2019. Explants were analyzed according to condition, mode of stimulation and other demographics using logistic regression and Kaplan-Meier graphs with log-rank (Mantel-Cox) test.

Results: Out of a total of 1177 patients, the explant rate was 17.8% at 5 years and 25.2% at 10 years. Loss of efficacy was the most frequent reason for explant 119/181 (65%). Multivariant regression analysis indicated patients with back pain without prior surgery had a reduced risk of explant (p=0.03). Patients with SCS systems that had 10 kHz, options of multiple waveforms, and rechargeable batteries also had a decreased risk of explant (p<0.001). None of these findings were confirmed when comparing Kaplan-Meier graphs, however. Contrary to other studies, we found gender and age were not independent variables for explant.

Conclusion: These data contribute to a growing list of explant data in the scientific literature and give indications of what factors contribute to long-term utilization of electrical neuromodulation devices.

Keywords: back pain; chronic pain; postoperative complications; spinal cord stimulation.

MeSH terms

  • Chronic Pain*
  • Humans
  • Logistic Models
  • Neuralgia*
  • Retrospective Studies
  • Spinal Cord Stimulation* / adverse effects